58 related articles for article (PubMed ID: 12050677)
1. Prognostic impact of HER-2 Subclonal Amplification in breast cancer.
Di Oto E; Brandes AA; Cucchi MC; Foschini MP
Virchows Arch; 2017 Sep; 471(3):313-319. PubMed ID: 28573512
[TBL] [Abstract][Full Text] [Related]
2. Controversies in the assessment of HER-2: more questions than answers.
Leong TY; Leong AS
Adv Anat Pathol; 2006 Sep; 13(5):263-9. PubMed ID: 16998320
[TBL] [Abstract][Full Text] [Related]
3. HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.
Fanotto V; Ongaro E; Rihawi K; Avallone A; Silvestris N; Fornaro L; Vasile E; Antonuzzo L; Leone F; Rosati G; Giuliani F; Bordonaro R; Scartozzi M; De Maglio G; Negri FV; Fasola G; Aprile G
Oncotarget; 2016 Oct; 7(42):69060-69074. PubMed ID: 27542243
[TBL] [Abstract][Full Text] [Related]
4. HER-2 Positive Breast Cancer - a Mini-Review.
Asif HM; Sultana S; Ahmed S; Akhtar N; Tariq M
Asian Pac J Cancer Prev; 2016; 17(4):1609-15. PubMed ID: 27221828
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET Targeting Receptor Tyrosine Kinase: Clinical Applications.
Linguanti F; Abenavoli EM; Calabretta R; Berti V; Lopci E
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136430
[TBL] [Abstract][Full Text] [Related]
6. Accuracy evaluation of combining gastroscopy, multi-slice spiral CT, Her-2, and tumor markers in gastric cancer staging diagnosis.
Zhao S; Bi Y; Wang Z; Zhang F; Zhang Y; Xu Y
World J Surg Oncol; 2022 May; 20(1):152. PubMed ID: 35545785
[TBL] [Abstract][Full Text] [Related]
7. Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results.
Kulka J; Tôkés AM; Kaposi-Novák P; Udvarhelyi N; Keller A; Schaff Z
Pathol Oncol Res; 2006; 12(4):197-204. PubMed ID: 17189981
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-erbB-2 and glutathione S-transferase-pi in hepatocellular carcinoma and its adjacent tissue.
Niu ZS; Wang M
World J Gastroenterol; 2005 Jul; 11(28):4404-8. PubMed ID: 16038042
[TBL] [Abstract][Full Text] [Related]
9. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
Carney WP
IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
[TBL] [Abstract][Full Text] [Related]
10. [HER-2 diagnostics].
Bánkfalvi A
Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
Ross JS; Gray GS
Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
[TBL] [Abstract][Full Text] [Related]
12. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
13. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
14. HER-2 status determination in breast carcinomas. A practical approach.
García-Caballero T; Menéndez MD; Vázquez-Boquete A; Gallego R; Forteza J; Fraga M
Histol Histopathol; 2006 Mar; 21(3):227-36. PubMed ID: 16372244
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
